Scarica l'app Stockscreener
11.56
2.78%
-0.33
Dopo l'orario di chiusura:
11.75
0.19
+1.64%
Precedente Chiudi:
$11.89
Aprire:
$12.04
Volume 24 ore:
1.46M
Relative Volume:
1.03
Capitalizzazione di mercato:
$544.36M
Reddito:
$217.11M
Utile/perdita netta:
$-651.19M
Rapporto P/E:
-0.8899
EPS:
-12.99
Flusso di cassa netto:
$-387.26M
1 W Prestazione:
-19.05%
1M Prestazione:
+15.83%
6M Prestazione:
-6.17%
1 anno Prestazione:
+10.31%
Intervallo 1D:
$11.41
$12.35
Intervallo di 1 settimana:
$11.41
$14.28
Portata 52W:
$5.00
$16.85
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Confronta DNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
11.56 | 703.89M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
Ginkgo Bioworks Holdings Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ginkgo Bioworks appoints Brian O’Sullivan as head of commercial By Investing.com - Investing.com Canada
Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth - PR Newswire
Ginkgo Bioworks: Sell The Recent Rally (NYSE:DNA) - Seeking Alpha
Comparing Ginkgo Bioworks Holdings Inc. in custom built stock radarsFree Swing Trade Entry With Volume Triggers - Newser
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.33 - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2025 Earnings Call Transcript - Insider Monkey
Ginkgo achieves $250M cost-reduction goal early, bolsters financial position - The Business Journals
Ginkgo Bioworks stock price target raised to $16 from $12 at TD Cowen - Investing.com Australia
Ginkgo Bioworks Holdings Inc (DNA) PT Raised to $16 at TD Cowen - StreetInsider
Ginkgo Bioworks Holdings Inc (DNA) Q2 2025 Earnings Call Highlights: Strategic Cost Management ... By GuruFocus - Investing.com Canada
Ginkgo Bioworks Holdings, Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Reports Q2 2025 Financial Results - TipRanks
Ginkgo Bioworks Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ginkgo Bioworks Q2 2025 Earnings Call Transcript - MarketBeat
Ginkgo Bioworks Holdings: Strong Growth Potential Amidst Biosecurity Revenue Challenges - TipRanks
Ginkgo Bioworks Reports Second Quarter 2025 Financial Results - The Malaysian Reserve
Ginkgo Bioworks Struggles As Biosecurity Revenue Slips - Finimize
Ginkgo Bioworks Holdings, Inc. SEC 10-Q Report - TradingView
Ginkgo Bioworks Announces Q2 Earnings Presentation on Aug. 7, 2025 - AInvest
Bank of New York Mellon Corp Raises Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
What makes Ginkgo Bioworks Holdings Inc. stock price move sharplyTechnical Reversal Setup with Risk Limits - Newser
Ginkgo Bioworks Holdings Inc expected to post a loss of $1.57 a shareEarnings Preview - TradingView
Ginkgo Bioworks Holdings Inc (DNA) Stock: A Year of Decreases and Increases - investchronicle.com
Quant Strategy Flags Ginkgo Bioworks Holdings Inc. for EntryLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Traders Consider Averaging Down in Ginkgo Bioworks Holdings Inc.Secure Return Focused Investment Plan Released - beatles.ru
How does Ginkgo Bioworks Holdings Inc. generate profit in a changing economyFree Investment Risk Control - Jammu Links News
Ginkgo Bioworks Holdings Inc. Stock Analysis and ForecastAccelerated wealth expansion - Jammu Links News
What catalysts could drive Ginkgo Bioworks Holdings Inc. stock higher in 2025Master stock selection with insider knowledge - Jammu Links News
What is the dividend policy of Ginkgo Bioworks Holdings Inc. stockExceptional profit potential - Jammu Links News
When is Ginkgo Bioworks Holdings Inc. stock expected to show significant growthGet alerts on the hottest stocks daily - Jammu Links News
Is it the right time to buy Ginkgo Bioworks Holdings Inc. stockBreakneck growth rates - Jammu Links News
How does Ginkgo Bioworks Holdings Inc. compare to its industry peersAchieve impressive returns with smart timing - Jammu Links News
What is the risk reward ratio of investing in Ginkgo Bioworks Holdings Inc. stockReal Time Planner For Fast Growth - jammulinksnews.com
Is Ginkgo Bioworks Holdings Inc. stock overvalued or undervaluedBeginner Investor Watchlist For 2025 - Jammu Links News
Ginkgo Bioworks shares fall 6.39% premarket ahead of Q2 2025 earnings presentation. - AInvest
Does Ginkgo Bioworks Holdings Inc. stock perform well during market downturnsAdvanced Screener Alerts That Work - Jammu Links News
Ginkgo Bioworks awarded $4.66M contract by PNNL - Yahoo Finance
Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation - 富途牛牛
Ginkgo Bioworks Q2 Earnings: Biosecurity Leader Sets August 7 Investor Call with Interactive Q&A - Stock Titan
Ginkgo Bioworks stock rises after securing $4.66M automation contract By Investing.com - Investing.com Canada
Ginkgo Bioworks Secures $4.66M Federal Contract for Revolutionary Lab Automation System at PNNL - Stock Titan
Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy - Ariva
Ginkgo Bioworks Holdings Inc. Flashes Rebound Signal in Oversold ConditionInvestment Plan With Growth Optimization Finalized - metal.it
Ginkgo Bioworks Holdings Inc. Stock Flags Risk Zone in Volatility IndexEarly Breakout Entry Point Notifications Sent - beatles.ru
Ginkgo Bioworks Holdings Inc. Breaks Below Key Support LevelSecure Capital Picks With Upside Potential Tracked - metal.it
What are analysts’ price targets for Ginkgo Bioworks Holdings Inc. in the next 12 monthsMaximize gains with proven stock analysis - jammulinksnews.com
How strong is Ginkgo Bioworks Holdings Inc. company’s balance sheetStay informed with daily expert analysis - jammulinksnews.com
What are the latest earnings results for Ginkgo Bioworks Holdings Inc.Achieve rapid portfolio appreciation today - Jammu Links News
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):